Harvey Klein is a Hematologist in Bethesda, Maryland. Dr. Klein is rated as an Advanced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Hemolytic Transfusion Reaction, Hemolysis, Anemia, Sickle Cell Disease, and Bone Marrow Transplant.

Swee Thein is a Hematologist in Bethesda, Maryland. Dr. Thein is rated as an Advanced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Anemia.

Jay Epstein is an Infectious Disease provider in Rockville, Maryland. Dr. Epstein is rated as an Advanced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Hemolytic Transfusion Reaction, Zika Virus Disease, and COVID-19.

Alan R. Cohen is the director of pediatric neurosurgery at Johns Hopkins Children’s Center in Baltimore, Maryland, and one of the top pediatric neurosurgeons in the country. His area of specialty is treating infants and children diagnosed with brain tumors. Dr. Cohen’s goal is to get his patients back to being a kid again. He has a patient-centered approach to caring for each of his patients, working closely with the child’s family at every stage of the decision-making process. Dr. Cohen sees patients in the neurosciences clinic located in the Levi Watkins, Jr., M.D., Outpatient Center. As the Carson-Spiro Professor of Pediatric Neurosurgery, Dr. Cohen is a leader in developing minimally invasive techniques to enhance the safety and efficacy of selected pediatric neurosurgical procedures. He serves as director of the Minimally Invasive Neurosurgery Laboratory at Johns Hopkins and directs the Minimally Invasive Neurosurgery Fellowship Program. His lab focuses on developing novel instruments and surgical approaches. He has authored more than 200 peer-reviewed journal articles and book chapters, and published two textbooks. He has given approximately 330 national and international presentations, and has been an invited visiting professor at 50 medical centers. He is past president of the Society of Neurological Surgeons, the American Society of Pediatric Neurosurgeons and the AANS/CNS Section on Pediatric Neurological Surgery. He is past vice president of the American Academy of Neurological Surgery, a past director of the American Board of Neurological Surgery and current director of the American Board of Pediatric Neurological Surgery. Patient Reviews Hear what patients have to say about Dr. Cohen’s care: • Healthgrades Patient Reviews • Vitals Patient Reviews. Dr. Cohen is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Arachnoid Cysts, Meningocele, Hydrocephalus, Endoscopy, and Cerebral Artery Bypass Surgery.

Karen Carroll is an Infectious Disease provider in Baltimore, Maryland. Dr. Carroll is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, Pneumonia, Meningitis, and Bone Marrow Aspiration. Dr. Carroll is currently accepting new patients.

Dr. Lydia H. Pecker is a pediatric hematologist and Director of the Young Adult Clinic at the Sickle Cell Center for Adults at Johns Hopkins. Dr. Pecker received her undergraduate degree in Africana studies from Brown University and earned her M.D. at the University of Pennsylvania School of Medicine. She completed residency training at Children’s Hospital at Montefiore and completed a fellowship at Children’s National Medical Center and the National Institutes of Health’s National Heart, Lung and Blood Institute before joining the Hopkins faculty in 2016. Dr. Pecker's NIH and foundation-funded research focuses on reproductive health in people with ovaries and sickle cell disease. Dr. Pecker is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Tubal Ligation.

Glenn Whitman, M.D., joined the Johns Hopkins Division of Cardiac Surgery in 2009 as associate professor of surgery. His training began at the University of Pennsylvania, where he was a resident in surgery from 1979 to 1984. He then finished his general surgery training and then completed his training as a cardiothoracic surgeon at the University of Colorado. Thereafter, Dr. Whitman became an assistant professor at the University of Colorado and chief of cardiothoracic surgery at the Denver Veteran’s Administration Hospital, where he remained for two years. In 1990, he returned to his home city of Philadelphia, where he became chief of cardiac surgery at the Medical College of Pennsylvania, formerly Women’s Medical College, the first medical school in the United States to accept women. Dr. Whitman remained there for eight years before moving to the University of Maryland as chief of cardiac surgery. He has served as the director of transplantation and United Network for Organ Sharing representative at Temple University Hospital in Philadelphia, as well as its director of perioperative services, managing preadmission testing, the operating room, and the post-anesthesia care unit. In 2007, he left Temple for Thomas Jefferson Hospital, taking over the responsibilities of running the cardiac surgery intensive care unit. In summer 2009, he was returned to Baltimore to run the cardiac surgery intensive care unit and oversee the performance improvement/quality assurance program for cardiac surgery at Johns Hopkins. Dr. Whitman’s initial research interests were in cardiac ischemia-reperfusion injury and P31 nuclear magnetic resonance of cardiac bioenergetics, for which he received both National Institutes of Health and Department of Veterans Affairs funding. He has since become involved with quality outcome, and has presented at the American College of Surgeons and the Society of Thoracic Surgeons on the difficulties associated with performance improvement and quality assurance in the field of health care, particularly in the ICU. This past year, Dr. Whitman has stepped down from his role as the Chair of the Society of Thoracic Surgery Workforce on Critical Care, a role he had held since 2014. He continues to participate in the content of the Annual Meetings for the Society of Thoracic Surgery, The American Association of Thoracic Surgery, and The STS Fall Critical Care meetings as the Programmatic Co-Chair for Perioperative Care. This past year he has participated in two major consensus statements on postcardiotomy shock (see below) and low ejection fraction CABG patients (awaiting review). 2020 EACTS/ELSO/STS/AATS ExpertConsensus on Post-CardiotomyExtracorporeal Life Support in Adult Patients Ann Thorac Surg 2012;111:327-69. Dr. Whitman is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Cardiogenic Shock, Restrictive Cardiomyopathy (RCM), Hemolysis, Heart Bypass Surgery, and Heart Transplant.

Jeremy Perkins is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Perkins is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Dysfibrinogenemia, Factor 11 Deficiency, Hemolytic Transfusion Reaction, and Breast Cancer.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Jeanne Sheffield is an Infectious Disease specialist and a Neonatologist in Baltimore, Maryland. Dr. Sheffield is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Congenital Syphilis, Placenta Previa, Zika Virus Disease, Microcephaly, and Hysterectomy.

James Gammie is the surgical lead and co-director for the Johns Hopkins Heart and Vascular Institute and cardiac surgeon-in-chief for the Johns Hopkins Health System. With over 23 years of experience in cardiothoracic surgery, Dr. Gammie joined Johns Hopkins after serving as chief of the division of cardiac surgery at the University of Maryland Medical Center from 2012 to 2021. Dr. Gammie graduated from Brown University with a degree in biochemistry, and received his medical degree from the University of Massachusetts Medical School. Dr. Gammie trained in both general and cardiothoracic surgery at the University of Pittsburgh School of Medicine. His clinical and research efforts are focused on decreasing the mortality and morbidity of valve disease and improving the surgical treatment of mitral valve and other structural heart diseases. He performs over 225 mitral valve operations and interventions per year, and leads a cardiac surgery team that performs more than 1,200 cardiac operations annually. He is recognized by the Mitral Foundation and the American Heart Association as one of less than 25 reference surgeons in the U.S. for his experience in mitral valve repair and excellent patient outcomes. Dr. Gammie has a strong interest in all aspects of heart valve disease, and has published more than 200 peer-reviewed contributions in leading specialty journals including The New England Journal of Medicine, the Journal of Thoracic and Cardiovascular Surgery and Circulation. He has served as a deputy editor for The Annals of Thoracic Surgery and as chair of the Access and Publications Committee of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. He serves on the steering committee of the NHLBI-sponsored Cardiothoracic Surgery Trials Network, and led the protocol development committee of a worldwide randomized tricuspid valve surgery trial. He is a member of the Halsted Society and the 21st Century Cardiothoracic Surgical Society. In 2011, Dr. Gammie was awarded the Johns Hopkins/University of Maryland Alliance for Science and Technology Development BioMaryland LIFE Prize, and he was named Entrepreneur of the Year at the University of Maryland Baltimore in 2014. He is the inventor of a novel transseptal catheter designed to simplify transcatheter cardiac procedures, and founded a commercial company to commercialize the device. With 20 issued or submitted patents, he continues to innovate in the mitral valve space, and recently published the world’s first clinical experience with a novel surgical repair for secondary mitral valve regurgitation, which was developed in his laboratory: mitral valve translocation. From 2016–2021, Dr. Gammie was consistently named a Top Doctor by Baltimore magazine, and in 2018 he received the Golden Apple Teacher of the Year award. Dr. Gammie is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Mitral Valve Regurgitation, Tricuspid Regurgitation, Mitral Valve Prolapse, Embolectomy, and Heart Bypass Surgery.

Dr. Thomas Quinn is professor of medicine and pathology in the Johns Hopkins School of Medicine and professor of international health, epidemiology, and molecular microbiology and immunology in The Johns Hopkins School of Public Health, and professor of nursing in the Johns Hopkins School of Nursing. In 2006 he was appointed founding Director of the Johns Hopkins University Center for Global Health. He serves as advisor/consultant on HIV and STDs to the World Health Organization, Office of the Global AIDS Coordinator (PEPFAR), UNAIDS, and the FDA. He serves as Associate Director for International Research at the National Institute of Allergy and Infectious Diseases. He is a member of the Institute of Medicine of the National Academy of Sciences, and is a fellow of the American Association for the Advancement of Science. He is a fellow of the Infectious Diseases Society of America and a member of the American Association of Physicians. He is an author of over 900 publications on HIV, STDs, and infectious diseases, and serves on multiple editorial boards. Among his professional activities, Dr. Quinn is an alternate member of the Technical Panel of the Global Fund to Fight AIDS, Malaria, and Tuberculosis and has been on Advisor/Consultant on HIV and STDs to the World Health Organization, UNAIDS, and the U.S. Food and Drug Administration. In October 2004 he received membership in the Institute of Medicine. Dr. Quinn is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are HIV/AIDS, Genital Herpes, Chlamydia, and Human Papillomavirus Infection.

Dr. Kelly Gebo is a graduate of The Johns Hopkins University School of Medicine. She also earned an MPH in Epidemiology from The Johns Hopkins Bloomberg School of Public Health. She completed residency training in Internal Medicine at The Johns Hopkins Hospital followed by an infectious diseases fellowship and two additional years of fellowship training as a Robert Wood Johnson Clinical Scholar, also at Hopkins. Her clinical and research interests include clinical outcomes and healthcare utilization research within infectious diseases. She was Director of the JHU Public Health Studies Program between the Krieger School for Arts and Sciences and the Bloomberg School for Public Health, was an American Council of Education Fellow (hosted at the University of Pennsylvania) and was the inaugural Vice Provost for Education at Johns Hopkins. She was on sabbatical at Stanford University School of Medicine 2019-20 and served as the Chief Medical and Scientific Officer for the All of Us Research Program 2018-2020. She currently serves as the director of the Johns Hopkins Clinical Research Scholars Program and is Deputy Director of the Johns Hopkins Institute for Clinical and Translational Research. She has mentored undergraduate, public health and medical students, trainees, and junior faculty on infectious diseases and health services projects. She has authored or co-authored numerous chapters and over 250 papers. She is a member of the American Society of Clinical Investigation and has been awarded the David Levine Prize for mentoring at Johns Hopkins. LinkedIn https://www.linkedin.com/in/kelly-gebo-13377811/. Dr. Gebo is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Jennifer Webb is a Hematologist and an Oncologist in Silver Spring, Maryland. Dr. Webb is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Sickle Cell Disease, Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Lucas Johnson is a primary care provider, practicing in Internal Medicine in Bethesda, Maryland. Dr. Johnson is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top area of expertise is Hemolytic Transfusion Reaction.

Susan Leitman is an Oncologist in Bethesda, Maryland. Dr. Leitman is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Hemochromatosis, Graft Versus Host Disease (GvHD), Aplastic Anemia, Anemia, and Bone Marrow Transplant.

Kana Fujikura is a Cardiologist in Bethesda, Maryland. Dr. Fujikura is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Saddle Pulmonary Embolism, Atherosclerosis, Aortic Valve Stenosis, and Cardiomyopathy.

Omar Taha is a Hematologist and an Oncologist in Clinton, Maryland. Dr. Taha is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Hemolytic Transfusion Reaction, Sickle Cell Disease, Subdural Hematoma, Pulmonary Embolism, and Endoscopy.

Young Kim is a Radiologist in Baltimore, Maryland. Dr. Kim is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are T-Cell Lymphoma, Varicose Veins, Nonalcoholic Steatohepatitis (NASH), Small Bowel Resection, and Sleeve Gastrectomy.